| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 12.611 | 61.485 | 90.937 | 64.940 | 87.123 | 85.561 | 87.385 | - | - | - |
| Total Income - EUR | 12.612 | 61.485 | 90.937 | 64.940 | 87.123 | 85.561 | 87.385 | - | - | - |
| Total Expenses - EUR | 12.000 | 54.685 | 82.738 | 54.040 | 78.178 | 79.131 | 81.594 | - | - | - |
| Gross Profit/Loss - EUR | 611 | 6.800 | 8.198 | 10.900 | 8.945 | 6.430 | 5.790 | - | - | - |
| Net Profit/Loss - EUR | 484 | 4.422 | 5.470 | 8.952 | 6.331 | 3.863 | 3.169 | - | - | - |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |
Check the financial reports for the company - Adyrom Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 29.561 | 27.067 | 24.670 | 40.984 | - | - | - |
| Current Assets | 12.153 | 8.181 | 12.549 | 8.449 | 9.420 | 16.551 | 11.507 | - | - | - |
| Inventories | 7.518 | 6.270 | 6.885 | 4.611 | 3.338 | 2.153 | 2.897 | - | - | - |
| Receivables | 3.925 | 544 | 2.852 | 2.368 | 2.623 | 9.964 | 6.504 | - | - | - |
| Cash | 710 | 1.367 | 2.812 | 1.471 | 3.459 | 4.434 | 2.106 | - | - | - |
| Shareholders Funds | -866 | 3.564 | 8.974 | 17.761 | 23.749 | 27.162 | 29.728 | - | - | - |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | - | - | - |
| Debts | 13.019 | 4.617 | 3.575 | 20.248 | 12.738 | 14.059 | 22.763 | - | - | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4619 - 4619" | |||||||||
| CAEN Financial Year |
4619
|
|||||||||
Comments - Adyrom Pharm Srl